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International, multicentre, parallel-group, prospective, superiority randomised trial with intentionto-treat analysis
Study patients
Inclusion criteria: Patients aged 10-65 years with traumatic brain injury (TBI) and refractory intracranial hypertension (>25 mmHg for 1-12 h despite 'Stage 1' and 'Stage 2' medical therapies), presenting to 52 acute neurosciences centres in 20 countries. Patients required an abnormal CT head scan and ICP monitor before randomisation. A prior craniotomy (but not craniectomy) was permitted. Exclusion criteria: Patients with bilateral fixed and dilated pupils, bleeding diathesis or injuries 'deemed unsurvivable' were pre-defined exclusions. A primary decompressive craniectomy, withdrawal of consent, 'lack of equipoise', and brainstem involvement were further reasons for exclusion. A total of 2008 patients were assessed for eligibility and 408 underwent randomisation; 10 were subsequently excluded.
Study groups
All study patients underwent stepwise medical management prior to randomisation. Stage 1 therapies included head elevation, controlled ventilation, sedation, and optional paralysis. Stage 2 therapies included vasopressors, ventriculostomy, therapeutic hypothermia, hypocapnia, and osmotherapy. At randomisation, 206 patients were then assigned to surgical intervention (either bi-frontal or unilateral decompressive craniectomy), and 202 patients were assigned to ongoing medical therapy (continuing Stage 1 and Stage 2 management, with the option to add barbiturates).
Results
At six months, there was lower mortality in the surgical group compared with the medical group (26.9% vs. 48.9%), but higher proportions of vegetative state (8.5% vs. 2.1%), lower severe disability (21.9% vs. 14.4%), and upper severe disability (15.4% vs. 8.0%) (see Table 1 ). For secondary outcomes, a similar pattern was observed in mortality and GOS-E distributions at 12 months. Baseline characteristics were similar between both groups, as were the proportions of Stage 1 and Stage 2 interventions (see Table 2 ). However, a large proportion (37.2%) of the medical treatment group later went on to have a decompressive craniectomy.
Evidence-based medicine questions
1. Do the methods allow accurate testing of the hypothesis? Yes. This was a large, multicentre randomised trial performed in neurosciences centres with 24-h access to neurosurgical and neurointensive care specialists. The baseline characteristics between groups were similar, and there was similar utilisation of Stage 1 and Stage 2 medical therapies prior to randomisation. Randomisation was performed in 1:1 permuted blocks of random size (stratified by trial site) in order to limit allocation bias. Although treating clinicians could not be blinded to group allocation, the trial statisticians and outcomes assessors were. 2. Do the statistical tests correctly test the results to allow differentiation of statistically significant results? No. The authors calculated 400 patients would be needed to provide 80% power to detect a 15% difference in rates of 'favourable' outcome between the treatment groups, and they managed to reach this recruitment target. However, during analysis, they found the data did not meet certain statistical assumptions underlying the ordinal regression analysis, and so common odds ratios could not be used. The subsequent analyses were therefore essentially descriptive. 3. Are the conclusions valid in light of the results?
Probably. However, there are several aspects of the study that deserve attention. Firstly, a large majority of patients were recruited in the UK (71.1%), where bifrontal craniectomies are used more often as the preferred surgical technique. 1 These operations are typically longer than unilateral craniectomies and associated with higher morbidity, 2 and this may have influenced the overall outcomes. Secondly, there was a high crossover rate in the medical group (37.2% subsequently had surgery); the authors maintain that the primary outcome was unchanged in a per-protocol analysis, but no data were presented to support this. Thirdly, recruitment occurred slowly over a 10-year period, during which time the medical management of TBI has changed in several important ways (e.g. temperature targets, the use of steroids, and accepted levels of hypocapnia). These changes may have influenced the trial outcomes over time, particularly in the medical group. Finally, when describing the results using This contrasts with similar studies (including the DECRA trial), which use lower moderate disability or better for their definition. When applying the conventional definition of 'favourable' outcome to this current study, any difference between the medical and surgical groups seems to disappear. 4. Did results get omitted and why? Yes. There was a very high exclusion rate. Over the 10 years of the study, 2008 patients were assessed for eligibility, yet 1599 were excluded. Whilst many of these appear to be for legitimate reasons (i.e. violation of pre-specified inclusion criteria), there were a number of exclusions for potentially arbitrary or subjective reasons (e.g. injuries 'deemed unsurvivable' (n ¼ 128); follow-up not possible (n ¼ 39); lack of equipoise (n ¼ 37); or no reason given at all (n ¼ 153)). Furthermore, after randomisation, 19 patients were excluded from the primary outcome analysis (5 in the surgical group, 14 in the medical group), due to withdrawal or lack of consent, and loss-to-follow-up. The authors used a 'modified' intention-to-treat analysis that excluded these data, but this is an unconventional approach that raises the possibility of a selection bias. 5. Did the authors suggest any further areas of research? Yes. The authors commented that their study did not look at long-term data on subsequent cranial reconstruction, which is an important part of the follow-up pathway for patients undergoing craniectomy. 6. Did they make any recommendations based on the results and are they appropriate? No. 7. Is the study relevant to my clinical practice? Yes.
TBI with raised ICP is a common condition associated with significant mortality and morbidity, and the evidence regarding how best to treat these patients is limited and often contradictory. Possibly. This study adds to the limited body of evidence that appears to show decompressive craniectomy results in more survivors but with higher rates of severe neurological impairment. Such data help to inform discussions with relatives when discussing the pros and cons of each treatment option, especially as quality-oflife considerations often play a central role in these decisions. 12. Should I audit my practice because of these results?
Yes. There is potential for wide variation in outcomes depending on a range of local factors (patient population and selection, departmental caseload, organisational factors). It also remains unclear a priori if there are particular subgroups of patients who are likely to benefit from a particular treatment strategy. Local data should better inform discussions with patient's relatives and enhance the decision-making process.
